311770-75-9

Upstream product

• 3300-51-4 p-Trifluoromethylbenzylamine 
• 79-37-8 oxalyl dichloride 
• 40751-89-1 2-methoxy-5-nitrobenzoic acid 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 311770-83-9 2-benzylsulfanyl-3-[4-methoxy-3-(4-trifluoromethyl-benzylcarbamoyl)-phenyl]-propionic acid ethyl ester 
• 311770-81-7 3-[4-methoxy-3-(4-trifluoromethyl-benzylcarbamoyl)-phenyl]-2-phenylsulfanyl-propionic acid ethyl ester 
• 311770-79-3 ethyl 2-ethylthio-3-[4-methoxy-3-[N-[[4-(trifluoromethyl)phenyl]methyl]carbamoyl]phenyl]propanoate 
• 311770-78-2 ethyl 2-bromo-3-[4-methoxy-3-[N-[[4-(trifluoromethyl)phenyl]methyl]carbamoyl]phenyl]propanoate 
• 311769-61-6 5-Amino-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]-benzamide 

Relevant academic research and scientific papers

Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) α

The invention provides novel substituted phenylpropanoic acid derivatives that activate by binding to receptor as ligands of human peroxisome preliferant-activated receptor α (PPARα), and exhibit potent decreasing action on lipids in blood (cholesterol an

Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor α subtype-selective activators

Substituted phenylpropanoic acid derivatives were prepared as part of a search for subtype-selective human peroxisome proliferator activated receptor α (PPARα) activators. Structure-activity relationship studies indicated that the nature and the stereoche

SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA(PPAR)

The invention provides novel substituted phenylpropanoic acid derivatives that activate by binding to receptor as ligands of human peroxisome preliferant-activated receptor α (PPARα), and exhibit potent decreasing action on lipids in blood (cholesterol and triglyceride). It relates to substituted phenylpropanoic acid derivatives represented by a general formula (1), their pharmaceutically acceptable salts and their hydrates, and processes for preparing them.

O-ANISAMIDE DERIVATIVES

The invention provides o-anisamide derivatives and their addition salts effective for the prevention and/or therapy of metabolic diseases such as hyperlipidemia and diabetes, in which peroxisome proliferator-activated receptor (PPAR) being intranuclear re